Dalbavancin as long-term suppressive therapy for patients with Gram-positive bacteremia due to an intravascular source-a series of four cases

We present four cases with Gram-positive bacteremia (pathogens: MRSAn = 1, Enterococcusspp.n = 3) due to an intravascular source (left ventricular assist device:n = 2, transfemoral aortic valve implantationn = 1, prosthetic aortic valve:n = 1) where no curative treatment was available. These patients received indefinite, chronic suppressive (palliative) therapy with dalbavancin (500 mg weekly or 1000 mg biweekly regimens). Outcomes and clinical characteristics are described; treatment was effective in suppression of bacteremia in all patients over several months (range: 1 to more than 12 months), we observed no relevant side effects.

Automated summary

Four cases of Gram-positive bacteremia originating from intravascular sources, including left ventricular assist devices, transfemoral aortic valve implantation, and prosthetic aortic valves, were effectively suppressed with dalbavancin therapy without significant side effects.